These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

659 related articles for article (PubMed ID: 15248926)

  • 1. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of treatment efficacy of the second and the third generations of chemoradiotherapy regimens containing platinum on advanced non-small cell lung cancer].
    Wang YM; Guo LJ; Li LS; Li P; Zheng J; Li L
    Ai Zheng; 2005 Dec; 24(12):1514-7. PubMed ID: 16351804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metallothionein expression in patients with small cell carcinoma of the lung: correlation with other molecular markers and clinical outcome.
    Joseph MG; Banerjee D; Kocha W; Feld R; Stitt LW; Cherian MG
    Cancer; 2001 Aug; 92(4):836-42. PubMed ID: 11550155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
    Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
    Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.
    Jeong SH; Jung JH; Han JH; Kim JH; Choi YW; Lee HW; Kang SY; Hwang YH; Ahn MS; Choi JH; Oh YT; Chun M; Kang S; Park KJ; Hwang SC; Sheen SS
    Lung Cancer; 2010 May; 68(2):288-94. PubMed ID: 19560836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.
    Siu LL; Banerjee D; Khurana RJ; Pan X; Pflueger R; Tannock IF; Moore MJ
    Clin Cancer Res; 1998 Mar; 4(3):559-65. PubMed ID: 9533522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic analysis of stage III-IV non-small cell lung cancer patients treated by traditional chinese medicine].
    Zhou DH; Lin LZ; Zhou YQ; Luo RC; Liu KF; Jia YJ; Chen JY; Niu XW; Su BR; Lu J; Wang ST
    Ai Zheng; 2005 Oct; 24(10):1252-6. PubMed ID: 16219143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
    Tsubochi H; Sato N; Hiyama M; Kaimori M; Endo S; Sohara Y; Imai T
    Ann Thorac Surg; 2006 Oct; 82(4):1198-204. PubMed ID: 16996907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
    Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer.
    Rusch V; Klimstra D; Venkatraman E; Oliver J; Martini N; Gralla R; Kris M; Dmitrovsky E
    Cancer Res; 1995 Nov; 55(21):5038-42. PubMed ID: 7585548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
    Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis.
    Yüksel M; Cermik TF; Doğanay L; Karlikaya C; Cakir E; Salan A; Berkarda S
    Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):876-81. PubMed ID: 12111127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
    Cobo M; Isla D; Massuti B; Montes A; Sanchez JM; Provencio M; Viñolas N; Paz-Ares L; Lopez-Vivanco G; Muñoz MA; Felip E; Alberola V; Camps C; Domine M; Sanchez JJ; Sanchez-Ronco M; Danenberg K; Taron M; Gandara D; Rosell R
    J Clin Oncol; 2007 Jul; 25(19):2747-54. PubMed ID: 17602080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer.
    Miyatake K; Gemba K; Ueoka H; Nishii K; Kiura K; Tabata M; Shibayama T; Takigawa N; Kawaraya M; Tanimoto M
    Anticancer Res; 2003; 23(3C):2829-36. PubMed ID: 12926120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
    Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
    Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [P53 protein expression and chemosensitivity to cisplatin in patients with non-small cell lung cancer: a meta-analysis].
    Wang JL; Jiao SC; Ye P; Li JY
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):770-3. PubMed ID: 18504201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.